Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule

Reviewer: Ryan P. Smith, MD
The Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 4 de julio del 2004

Translation for this article does not exist

Blogs

Cancer and Hair Loss
by Bob Riter
February 11, 2016